Sonoma Pharmaceuticals, Inc..
SNOA.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Sonoma Pharmaceuticals, Inc. is a global healthcare company specializing in the development and production of stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care, and dermatological conditions. The company's products ar...Show More
Better Health for All
0
Sonoma Pharmaceuticals' core products, based on HOCl technology, are clinically proven to provide exceptional health benefits, including reducing itch, pain, scarring, and irritation, managing various skin, wound, and respiratory conditions, and removing microorganisms.
1
The company's entire business is devoted to health improvement through these products. The company explicitly states its products are safe and non-toxic, and it does not use ingredients like benzoyl peroxide, which has been linked to benzene formation in competitor products, indicating no significant negative health impacts from its offerings.
2
However, the company's research and development expenses were $1,814,000 in 2025 and $1,871,000 in 2024.
3
When compared to its 2024 revenue of $12,735,000,
4
this represents approximately 14.7% of revenue, which falls into the -10 tier for health innovation investment. During the COVID-19 pandemic, the company's Nanocyn® Disinfectant & Sanitizer received approval for use against the virus in Australia and Canada.
5
However, there is no evidence of broader actions, significant flexibility, or contributions during global health crises, which suggests a reactive and limited crisis response.
Fair Money & Economic Opportunity
0
No evidence available to assess Sonoma Pharmaceuticals, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
Sonoma Pharmaceuticals is not a party to any collective bargaining agreements.
1
The company has a Compensation Clawback Policy, effective October 2, 2023.
2
The company contributes to a qualified 401(k) plan, matching employee contributions up to 4% of salary.
3
Company contributions were $88,000 for the year ended March 31, 2025, and $82,000 for the year ended March 31, 2024.
4
Reviews mention benefits, but no specific health insurance coverage percentages are provided.
5
No substantiated labor-law or human-rights violations have been reported in the provided articles.
6
Fair Trade & Ethical Sourcing
0
No evidence available to assess Sonoma Pharmaceuticals, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
0
No specific, concrete data points were found in the provided articles for any of the KPIs related to Honest & Fair Business.
1
The articles either explicitly state that information is not mentioned, not provided, or do not offer sufficient detail to meet the quantitative thresholds of the rubric.
2
Therefore, all KPIs for this value must be omitted.
Kind to Animals
-50
The company employs in-vitro studies for product safety and efficacy, specifically for managing skin abrasions, lacerations, minor irritations, cuts, and intact skin.
1
However, the extent of their use compared to other methods is not specified. For research and development, the company invested $1,871,000 in 2024 and $207,000 in 2023 in its core hypochlorous acid technology,
2
but no specific percentage of this budget is stated as being allocated to animal-free technologies or alternatives.
No War, No Weapons
0
No evidence available to assess Sonoma Pharmaceuticals, Inc. on No War, No Weapons.
Planet-Friendly Business
0
Sonoma Pharmaceuticals' Nanocyn® Hospital-Grade Disinfectant has received Green Seal® Certification, indicating adherence to rigorous environmental health, sustainability, and product performance standards.
1
This product, along with Microcyn OTC and Rejuvacyn Advanced, has also been certified as a Natural Personal Care Product by the Natural Products Association.
2
Nanocyn® is further recognized by Good Environmental Choice Australia (GECA) as an eco-certified, all-natural disinfectant solution.
3
The company's dermatology products are stated to contain all-natural ingredients and no harmful chemicals.
4
Sonoma Pharmaceuticals' products comply with OSHA requirements for occupational exposure and waste disposal regulations under the Resource Conservation and Recovery Act.
5
The company's facility in Zapopan, Mexico, is ISO 13485 certified.
6
Respect for Cultures & Communities
0
The provided articles contain no specific, concrete data points or facts related to Sonoma Pharmaceuticals' engagement with local or indigenous communities, cultural impact assessments, community investments, local employment, grievance mechanisms, cultural preservation, or any other metric under the 'Respect for Cultures & Communities' value.
1
The articles primarily focus on financial performance, regulatory clearances, product certifications, and job openings, explicitly stating the absence of data for community and cultural metrics.
Safe & Smart Tech
0
The company's facility is certified and complies with U.S. Current Good Manufacturing Practices, Quality Systems Regulations for medical devices, and ISO guidelines, including ISO 13485.
1
It has obtained 22 U.S. FDA 510(k) clearances and received an updated CE certificate under the new EU Medical Devices Regulation covering all commercialized products in Europe as of January 29, 2025.
2
The company is subject to HIPAA regulations and states that users can request access and changes to their information, which is a standard practice.
3
Zero Waste & Sustainable Products
0
Sonoma Pharmaceuticals' manufacturing facility in Zapopan, Mexico, complies with U.S., Mexican, and international Current Good Manufacturing Practices, Quality Systems Regulations for medical devices, and ISO guidelines, indicating standard hazardous waste management practices.
1
The company's wound treatment solution is noted for its unique chemistry, which provides superior stability and maintains higher levels of hypochlorous acid over its shelf life compared to similar products on the market.
2